Open Access
ISSN 2577-5820
© 2021 by the authors; CC BY 4.0 licence
OBM Transplantation , Volume 5 , Issue 4 (2021)
Pages: 50
Published: May 2022
(This book is a printed edition that was published in OBM Transplantation)
Cover story:Due to increasing shortages in the number of organs available for kidney transplants, transplantation with HCV and HIV-positive deceased donor kidneys has become a viable solution to this problem. The use of Hepatitis C and HIV donors is a cost-effective way to increase the rates of transplantation. View this paper.
Volume 5,Issue 4
The Donor – Recipient Weight Ratio is a Reliable Marker for Cell Yield in Hematopoietic Stem Cell DonationsAbstract Bone marrow transplants remain an import source of hematopoietic stem cells for patients suffering from specific diseases like aplastic anemia, for pediatric patients with malignant and non-malignant blood cell disorders, and for situations in which graft-versus-host disease (GvHD) is a [...] |
Adipose Tissue as a Useful Material for the Grafting of Tumorigenic Cells and Juvenile Tissues in MiceAbstract Although the aging process expands the adipose tissue habitation in mice and due to its close association with the female reproductive system, it can be easily exposed surgically under anesthesia when reproductive organs (including ovary, oviduct, and part of the [...] |
Economic Considerations in Using HCV and HIV Positive Donors for Kidney TransplantAbstract End Stage Renal Disease is becoming more prevalent in the United States of America, with demand for kidney transplant exceeding the available organ supply. A novel method to increase the donor pool has been to consider transplanting organs from deceased patients who have had Hepatitis C [...] |
Experience with Alpha-1 Proteinase Replacement Post-Lung Transplantation in Alpha-1 Antitrypsin Deficiency: A Single Center Case Seriesby
Kamyar Afshar
,
Michelle Bremer
,
Bharath Ravichandran
,
Ashley Feist
,
Eugene Golts
,
Elizabeth Schonhoft
and
Gordon Yung
Abstract Alpha-1 antitrypsin deficiency (AATD) accounts for approximately 5% of lung transplants (LTx) performed annually. No studies have addressed the potential benefit of ongoing alpha-1 proteinase inhibitor (A1-PI) replacement to AATD patients post-LTx. Our primary objective was to assess pot [...] |
TOP